Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer settles Celebrex/Bextra litigation

Executive Summary

Pfizer agrees to pay $894 million to resolve more than 90 percent of personal injury claims involving its COX-2 inhibitors, as well as consumer fraud class action claims and litigation by state attorneys general. The figure is less than half of the firm's annual Celebrex sales, which totaled $2.3 billion in 2007. Plaintiffs lawyers who worked on the structure of the settlement said the parties sought to avoid the model Merck used in settling Vioxx litigation (1"The Pink Sheet," Nov. 12, 2007, p. 11). Scott Nealey, a partner at Lieff Cabraser Heimann & Bernstein, which served as plaintiffs' liaison counsel, said that the settlement was designed so that plaintiffs will get paid quickly

Related Content

UsernamePublicRestriction

Register

PS050243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel